Purpose: The presence of multiple serial organs at risk (OARs) in close proximity to the tumor makes treatment planning for glioblastoma (GBM) complex and time consuming. The present study aimed to create a knowledge-based (KB) radiation therapy model for GBM patients using RapidPlan.
Methods And Materials: An initial model was trained using 82 glioblastoma patients treated with 60 Gy in 30 fractions. Plans were created using either volumetric modulated arc therapy (VMAT) or intensity modulated radiation therapy (IMRT). To improve the goodness-of-fit of the model, an intermediate model was generated by using the dose-volume histograms (DVHs) of best spared OARs of the initial model. Using the intermediate model and manual refinement, all 82 cases were replanned, resulting in the final model. The final model was validated on an independent set of 45 patients with GBM, astrocytoma, oligodendroglioma, and meningioma.
Results: The plans created by the final model exhibited superior planning target volume (PTV) dose metrics compared with manual clinical plans: ΔD=-0.52 ± 0.20 Gy, and ΔD=0.80 ± 0.13 Gy (differences are computed as clinical-model). OAR maximum doses were statistically similar, with improved optic apparatus sparing (ΔD=2.78 ± 0.82 Gy). Stated improvements correspond to P<.05. The KB planning time is typically 7 minutes for IMRT and 13 minutes for VMAT, compared with a typical 4 hours for manual planning.
Conclusions: The KB approach results in significant improvement in planning efficiency and in superior PTV coverage and better normal tissue sparing irrespective of tumor size and location within the brain.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijrobp.2017.07.012 | DOI Listing |
Heliyon
January 2025
BRITElab, Harry Perkins Institute of Medical Research, QEII Medical Centre Nedlands and Centre for Medical Research, The University of Western Australia, Perth, Australia.
Breast-conserving surgery accompanied by adjuvant radiotherapy is the standard of care for patients with early-stage breast cancer. However, re-excision is reported in 20-30 % of cases, largely because of close or involved tumor margins in the specimen. Several intraoperative tumor margin assessment techniques have been proposed to overcome this issue, however, none have been widely adopted.
View Article and Find Full Text PDFCureus
December 2024
Surgery, The Royal Wolverhampton NHS Trust, Wolverhampton, GBR.
Background Pre-pectoral implant-based breast reconstruction has become increasingly popular because it is associated with less postoperative pain and earlier recovery than traditional sub-pectoral techniques. Acellular dermal matrix (ADM) in pre-pectoral reconstruction is thought to provide additional support for the implant and improve cosmetic outcomes. However, it leads to additional costs.
View Article and Find Full Text PDFCureus
December 2024
Hematology/Oncology, University of Kansas Medical Center, Kansas City, USA.
A 58-year-old male, with a history of human immunodeficiency virus (HIV) and stage 4 left frontotemporal squamous cell carcinoma (SCC), presented with new-onset neck pain. He was diagnosed with HIV five years prior. The patient had a cluster of differentiation 4 (CD4) count of 53 cells/mm³ and a high viral load, later suppressed with bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy).
View Article and Find Full Text PDFCureus
December 2024
Department of Ophthalmology, University General Hospital of Heraklion, Heraklion, GRC.
Orbital apex lesions represent a clinical challenge since they are difficult to remove surgically and may induce significant functional defects. The orbital apex is an area of convergence of neurovascular elements passing through the various local osseous foramina and the congestion of several critical anatomical structures in a confined space increases the risk of intraoperative complications. Radiotherapy is an alternative treatment option in such cases but may also induce radiation toxicity.
View Article and Find Full Text PDFJ Bone Oncol
February 2025
Unit of Oral Medicine and Dentistry for Frail Patients, Department of Rehabilitation, Fragility, and Continuity of Care, Regional Center for Research and Care of MRONJ, University Hospital Palermo, Palermo, PA, Italy.
Background: Low-doses of bone modifying agents (LD-BMAs) compared to those used to treat bone metastases are used in breast or prostate cancer patients on adjuvant endocrine therapy to prevent Cancer Treatment Induced Bone Loss (CTIBL). Their use is associated with an increased risk of developing Medication-Related Osteonecrosis of the Jaw (MRONJ). However, there is not clarity about strategies aimed to minimize the MRONJ risk in cancer patients at different conditions as low- vs high-doses of BMA.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!